Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss

Company Still Sees Profit Potential Even With US Generic Competitors

Executive Summary

A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.

You may also be interested in...



Amarin Steps Closer To EU Cardiovascular Risk Market

The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.

Amarin Builds Sales Infrastructure For EU Vazkepa Launch

With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.

Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug

The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel